Posts Tagged ‘liraglutide’

Can’t, Won’t, Don’t: Why People Stop Taking Obesity Medicines

May 30, 2024 — In a world that systematically denies people access to obesity medicines, the rush of reports that people frequently stop taking them makes us wonder. How does this qualify as news? Why do reporters repeatedly paint a misleading picture of non-compliant patients? Yet, health reporters keep offering up this narrative. The latest prompt for this is […]

“Weight Loss Jabs” Instead of Drug Rehab? Hold On, Folks

February 24, 2024 — This sounds like a godsend. “Weight loss jabs could be a more effective and cheaper treatment for drug addiction than rehab, a study suggests.” So says the Telegraph of London. The “weight loss jabs” they’re talking about are liraglutide 3 mg daily injections, also known by the brand name of Saxenda. Sad to say, they […]

A Surge in Pediatric Obesity Treatment? Or a Small Uptick?

February 17, 2024 — Reporting for Reuters, Robin Respaut and Chad Terhune tell us that prescription data in the U.S. reveals increasing use of semaglutide for obesity in adolescents. Does this signal a huge surge in pediatric obesity treatment? Or merely a small uptick from almost negligible access to care? That all depends on the story you want to […]

Weight Regain in the Real World vs a Placebo-Controlled Trial

January 30, 2024 — It created quite a stir last week when Epic Research published an analysis suggesting that weight regain in the real world does not look the same as a placebo-controlled trial. After all, regain is quite an important subject. Obesity is clearly a chronic disease, requiring chronic care. But lots of people try to avoid this […]

Real World Data Say Not Everyone Regains All Their Weight

January 25, 2024 — One of the more annoying generalizations in obesity is the assertion that when people lose weight, everyone inevitably regains it all and perhaps even more. When said about metabolic surgery, it’s utterly false. But that doesn’t stop people from saying it – even people who pose as medical experts. More broadly in the medical management […]

Might Semaglutide Prompt Less Alcohol Use?

March 8, 2023 — We would classify this as a report of a side effect. But it’s not really an adverse event. It seems that for some people, the use of semaglutide has prompted less alcohol use. In the New York Times, Dani Blum describes the experience of one patient: “In August 2022, Eva Monsen’s endocrinologist prescribed Ozempic [semaglutide] […]

Brands That Keep Obesity Separate and Unequal

November 20, 2022 — Fed up. That’s where we are with stories about how people taking semaglutide for obesity are keeping people with diabetes from getting an adequate supply of the drug they need. Fed up, because it’s a stealthy way of expressing implicit bias against people living with obesity. The subtext is that those people don’t really need […]

Costly and Effective versus Cheap and Ineffective

September 3, 2022 — ICER – the Institute for Clinical and Economic Review – has released its final report on the effectiveness and value of obesity meds and set a public hearing for September 16. Let’s say it right up front. This private nonprofit is trying to do something that is almost impossibly hard. Making objective sense from the […]

Chasing Hoops for Obesity Care

August 1, 2022 — In the New York Times recently, our friend Maya Cohen described her experiences chasing the hoops set before her by health insurance – interfering with medically necessary obesity care. But she did not stop there. She came to the YWM Engage conference to connect with and inspire other advocates for people living with obesity. So […]

Suddenly Bullish on Anti-Obesity Medicines?

January 12, 2022 — It’s been a long haul. But suddenly, we’re seeing a lot of optimism about anti-obesity medicines. Skeptics are yielding to stubborn facts about the impact of obesity on health. They are also yielding to good clinical data about the benefits of sound obesity care. So, too, are they seeing that newer generations of anti-obesity medicines […]